Therefore, these observations indicate that KIF20A may promote CRC cell growth and migration through JAK/STAT3-dependent mechanisms and suggest that KIF20A can be further evaluated as a potential therapeutic target for CRC. This evidence concerns the gene KIF20A and colorectal carcinoma.